Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study
- PMID: 15020614
- DOI: 10.1200/JCO.2004.04.165
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study
Abstract
Purpose: To compare fotemustine and dacarbazine (DTIC) in terms of overall response rate (ORR) as primary end-point and overall survival, duration of responses, time to progression, time to occurrence of brain metastases (BM), and to assess safety and quality of life in patients with disseminated cutaneous melanoma.
Patients and methods: Patients received either intravenous fotemustine 100 mg/m2 weekly for 3 weeks or DTIC 250 mg/m2/d for 5 consecutive days every 4 weeks (two cycles). Nonprogressive patients received a maintenance treatment every 4 weeks (fotemustine 100 mg/m2 or DTIC 250 mg/m2 for 5 days).
Results: Two hundred twenty-nine patients were randomly assigned to fotemustine or DTIC arms. The best ORR was higher in the fotemustine arm than in the DTIC arm in the intent-to-treat population (n=229; 15.2% v 6.8%; P=.043) and in full analysis set (n=221) (15.5% v 7.2%; P=.053). Similar median durations of responses (5.8 months with fotemustine v 6.9 months with DTIC) and time to progression (1.8 v 1.9 months, respectively) were observed. In patients without BM at inclusion, the median time to BM was 22.7 months with fotemustine versus 7.2 months with DTIC (P=.059). Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively). No significant difference was noted for quality of life between arms.
Conclusion: ORR was higher in the fotemustine arm compared to the DTIC arm in first-line treatment of disseminated melanoma. A trend in favor of fotemustine in terms of overall survival and time to BM was evidenced.
Similar articles
-
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.Cancer. 2000 Dec 15;89(12):2630-6. Cancer. 2000. PMID: 11135225 Clinical Trial.
-
[Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].Ann Dermatol Venereol. 1993;120(6-7):437-40. Ann Dermatol Venereol. 1993. PMID: 8279787 French.
-
[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].Ann Dermatol Venereol. 1995;122(10):663-6. Ann Dermatol Venereol. 1995. PMID: 8687048 French.
-
Fotemustine in the treatment of brain primary tumors and metastases.Cancer Invest. 1994;12(4):414-20. doi: 10.3109/07357909409038234. Cancer Invest. 1994. PMID: 8032964 Review.
-
[Contribution of a new nitrosourea compound: fotemustine].Pathol Biol (Paris). 1992 Dec;40(9 Pt 2):964-8. Pathol Biol (Paris). 1992. PMID: 1338920 Review. French.
Cited by
-
GPR168 functions as a tumor suppressor in mouse melanoma by restraining Akt signaling pathway.PLoS One. 2024 May 28;19(5):e0302061. doi: 10.1371/journal.pone.0302061. eCollection 2024. PLoS One. 2024. PMID: 38805406 Free PMC article.
-
Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases.Curr Treat Options Oncol. 2023 Dec;24(12):1962-1977. doi: 10.1007/s11864-023-01155-3. Epub 2023 Dec 30. Curr Treat Options Oncol. 2023. PMID: 38158477 Review.
-
Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.Med Oncol. 2023 Dec 21;41(1):24. doi: 10.1007/s12032-023-02245-w. Med Oncol. 2023. PMID: 38123873 Review.
-
PAK1 and Therapy Resistance in Melanoma.Cells. 2023 Sep 28;12(19):2373. doi: 10.3390/cells12192373. Cells. 2023. PMID: 37830586 Free PMC article. Review.
-
The role of mitochondria in the resistance of melanoma to PD-1 inhibitors.J Transl Med. 2023 May 23;21(1):345. doi: 10.1186/s12967-023-04200-9. J Transl Med. 2023. PMID: 37221594 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical